Mark A. Velleca - 08 Aug 2023 Form 4 Insider Report for G1 Therapeutics, Inc.

Role
Director
Signature
/s /Sandi James, attorney-in-fact
Issuer symbol
N/A
Transactions as of
08 Aug 2023
Net transactions value
-$96,818
Form type
4
Filing time
10 Aug 2023, 16:11:04 UTC
Previous filing
16 Jun 2023
Next filing
18 Sep 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $22,342 +57,286 +49% $0.3900* 173,286 08 Aug 2023 Direct
transaction GTHX Common Stock Sale $114,492 -57,286 -33% $2.00 116,000 08 Aug 2023 Direct F1, F2
transaction GTHX Common Stock Options Exercise $814 +2,714 +2.3% $0.3000* 118,714 08 Aug 2023 Direct
transaction GTHX Common Stock Sale $5,482 -2,714 -2.3% $2.02 116,000 08 Aug 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Option (Right to Buy) Options Exercise $0 -57,286 -100% $0.000000* 0 08 Aug 2023 Common Stock 57,286 $0.3900 Direct F3
transaction GTHX Stock Option (Right to Buy) Options Exercise $0 -2,714 -1.1% $0.000000 242,286 08 Aug 2023 Common Stock 2,714 $0.3000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $1.98 and a high of $2.06. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
F3 All shares underlying this option have vested.